
UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))



TO THE ASSISTANT COMMISSIONER FOR PATENTS

6	Box Patent Application Washington, D.C. 20231						
Transmitted he	rewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an						
	immunotherapy for solid nonlymphoid tumor and related immune dysregulation						
and invented b	у:						
Emilio Barbo	era-Guillem						
Jf_a CONTINU	ATION APPLICATION, check appropriate box and supply the requisite information:						
Continua	ation Divisional Continuation-in-part (CIP) of prior application No.: 09/411,116						
Which is a: Continua	ation Divisional Continuation-in-part (CIP) of prior application No.:						
Which is a:	ation — Divisional — Continuation-in-part (on) of prior apprication (vo.)						
Continua	ation Divisional Continuation-in-part (CIP) of prior application No.:						
3							
Enclosed are:	Application Elements						
Enclosed are:	ing fee as calculated and transmitted as described below						
<u>1 </u>	pecification having 66 pages and including the following:						
2. ⊠ Sp I	pecification having66 pages and including the following:						
a. 🛚	Descriptive Title of the Invention						
b. ⊠	Cross References to Related Applications (if applicable)						
c. 🗆	Statement Regarding Federally-sponsored Research/Development (if applicable)						
d. 🗔	Reference to Microfiche Appendix (if applicable)						
e. ⊠	Background of the Invention						
f. ⊠	Brief Summary of the Invention						
g. 🗵	Brief Description of the Drawings (if drawings filed)						
h. ⊠	Detailed Description						
i. 🗵	Claim(s) as Classified Below						

j. 🛛 Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **B-63**

Total Pages in this Submission
Sheets 272

	Application Elements (Continued)							
3.	☑ Drawing(s) (when necessary as prescribed by 35 USC 113)							
	a.	■ Formal						
4. 🗵 Oath or Declaration								
	a.	☑ Newly executed (original or copy) ☐ Unexecuted						
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)						
	c.	☑ With Power of Attorney ☐ Without Power of Attorney						
ट्य <u>े</u> सर्वे	d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).						
3 5 5		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.						
6.		Computer Program in Microfiche						
Ţ. ☐ Genetic Sequence Submission (if applicable, all must be included)								
7. F	a.	☐ Paper Copy						
den.	b.	□ Computer Readable Copy						
	c.	☐ Statement Verifying Identical Paper and Computer Readable Copy						
		Accompanying Application Parts						
8.	X	Assignment Papers (cover sheet & documents)						
9.		37 CFR 3.73(b) Statement (when there is an assignee)						
10.		English Translation Document (if applicable)						
11.	X	Information Disclosure Statement/PTO-1449 Copies of IDS Citations						
12.		Preliminary Amendment						
13.	X	Acknowledgment postcard						
14.	X	Certificate of Mailing						
• •	_	☐ First Class ☒ Express Mail (Specify Label No.): EL497108984US						

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **B-63**

Total Pages in this Submission

	Accompanying Application Parts (Continued)					
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)				
16.	X	Small Entity Statement(s) - Specify Number of Statements Submitted:				
17.		Additional Enclosures (please identify below): Applicant is a small entity within the meaning of 37 C.F.R. 1.27 & 1.9				
		Applicant is a small entity within the meaning of 57 C.F.R. 1.27 & 1.9				
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)				
18. 1		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.				
T T		Warning				
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.				

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **B-63**

Total Pages in this Submission Sheets

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra		Rate	Fee
Total Claims	67	- 20 =	47	×	\$9.00	\$423.00
Indep. Claims	8	- 3 =	5	x	\$40.00	\$200.00
	Multiple Dependent Claims (check if applicable) ☐ \$0.00					
and the second s					BASIC F	FEE \$355.00
OTHER FEE (spec	cify purpose)		assignmen	recorda	l	\$40.00
					TOTAL FILING	FEE \$1,018.00
A check in the amount of \$1,018.00 to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge and credit Deposit Account No. 500438 as described below. A duplicate copy of this sheet is enclosed. Charge the amount of as filing fee. Credit any overpayment. Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).						
Dated: 06 April 20	001			\mathfrak{M}_{i}	Bud Mh	_

M. Bud Nelson Reg. No. 35,300 Signature

CC:

CERTIFICATE OF I	Docket No. B-63						
Serial No.	Filing Date // // // // // // // // // // // // /	Examiner	Group Art				
Invention: Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation							
I hereby certify that the	I hereby certify that the following correspondence: patent application						
is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 April 2001							
Togo uji	Note: Each paper must h	ave its own certificate of mailing.					